Routes of Drug Administration

1. Introduction / Overview

Effective pharmacotherapy is contingent upon the successful delivery of a drug to its intended site of action. The route of administration determines the pharmacokinetic profile, therapeutic efficacy, safety, and patient adherence. This chapter provides a systematic examination of the principal routes of drug administration, delineating their characteristics, advantages, limitations, and clinical implications. It is intended as a reference for medical and pharmacy students who require a comprehensive understanding of how administration routes influence drug performance.

• To identify and describe the major routes of drug administration and their classification.
• To analyze how each route affects absorption, distribution, metabolism, and excretion.
• To evaluate therapeutic indications, adverse effect profiles, and interaction potentials associated with each route.
• To recognize special considerations for specific populations and disease states.

2. Classification of Routes of Administration

2.1. Systemic Routes

Systemic routes introduce the drug into the circulatory system, allowing widespread distribution to target tissues. They include:

• Oral (PO)
• Intravenous (IV)
• Intramuscular (IM)
• Subcutaneous (SC)
• Transdermal (TD)
• Inhalation (Inhaled)
• Intrathecal (IT)
• Intracerebral (IC)

2.2. Localized Routes

Localized routes deliver the drug directly to the target site, minimizing systemic exposure. They encompass:

• Topical (Skin)
• Rectal
• Buccal
• Sublingual
• Intranasal
• Intravaginal
• Intraocular
• Intramuscular (in muscle for localized effect)

2.3. Transmucosal Routes

Transmucosal routes exploit the rich vascularization of mucosal surfaces to achieve rapid absorption. Examples are:

• Buccal
• Sublingual
• Nasally

2.4. Enteral Routes

Enteral routes involve ingestion or administration via the gastrointestinal tract, including oral and rectal administration.

2.5. Inhalational Routes

Inhalation delivers drugs to the pulmonary system, providing systemic or local therapeutic effects. Types include:

• Metered‑dose inhalers (MDI)
• Dry powder inhalers (DPI)
• Nebulizers
• Inhaled aerosols (e.g., for systemic delivery)

3. Mechanism of Action by Route

3.1. Oral Administration

After ingestion, drugs traverse the oral cavity, esophagus, and stomach before reaching the small intestine, where dissolution and absorption occur. First‑pass metabolism in the liver may reduce bioavailability, particularly for drugs with high hepatic extraction ratios. The systemic absorption of orally administered drugs is mediated by passive diffusion, active transport, or facilitated diffusion across intestinal epithelium. The pharmacodynamic effect is influenced by the rate of absorption and peak plasma concentration (C_max).

3.2. Intravenous Administration

Intravenous delivery introduces the drug directly into the vascular compartment, bypassing absorption barriers. The pharmacokinetics are governed by distribution, metabolism, and excretion. Immediate systemic exposure allows rapid onset of action. The drug’s effect is determined by its concentration at the target site, with negligible first‑pass metabolism.

3.3. Intramuscular and Subcutaneous Administration

Drug particles are deposited into the muscle or subcutaneous tissue, respectively, where they are absorbed into the capillary network. The absorption rate is dependent on blood flow, drug solubility, and formulation. IM injections typically achieve faster absorption than SC due to higher vascularity. The pharmacodynamic response is delayed relative to IV but can be sustained for extended periods.

3.4. Transdermal Administration

Transdermal patches or gels enable drug permeation through the stratum corneum and into systemic circulation. The drug’s physicochemical properties—molecular weight (< 500 Da), lipophilicity (logP 1–3), and solubility—are critical determinants of permeation. Transdermal delivery provides a steady plasma concentration, minimizing peaks and troughs associated with oral dosing.

3.5. Topical Administration

Topical formulations (creams, ointments, lotions) apply directly to the skin surface. Drug penetration is limited by the stratum corneum, but formulations may contain penetration enhancers or utilize occlusive dressings to facilitate absorption. The therapeutic effect is primarily local, though systemic absorption can occur for lipophilic agents or in large surface area applications.

3.6. Inhalation Administration

Inhaled drugs deposit in the respiratory tract, reaching alveolar or bronchial sites. The alveoli provide a large surface area and thin epithelial barrier, enabling rapid systemic absorption. For local pulmonary therapies, deposition in the bronchioles or alveoli allows targeted action with reduced systemic exposure. Particle size, aerosol velocity, and patient inhalation technique influence deposition patterns.

3.7. Transmucosal Administration

Buccal, sublingual, and nasal mucosa provide rich capillary networks and thin mucosal layers, permitting rapid drug absorption into systemic circulation. The bypass of first‑pass metabolism yields higher bioavailability for certain drugs (e.g., nitroglycerin, naloxone). The mucosal route can be advantageous for drugs requiring rapid onset.

3.8. Intrathecal, Intracerebral, and Intraocular Administration

Administering drugs directly into the cerebrospinal fluid (CSF) or ocular compartments circumvents the blood‑brain barrier (BBB) or blood‑aqueous barrier, respectively. This approach is reserved for drugs with central nervous system (CNS) or ocular indications where systemic delivery is inadequate or undesirable. The pharmacodynamic effect is localized to the CNS or eye, with minimal systemic distribution.

4. Pharmacokinetics by Route

4.1. Absorption

Absorption characteristics differ markedly across routes. Oral absorption is subject to dissolution, intestinal permeability, and first‑pass metabolism; IV bypasses absorption entirely; IM and SC absorption is influenced by local blood flow; transdermal absorption depends on skin permeation; inhalation absorption is governed by deposition and alveolar transit; transmucosal absorption is rapid due to mucosal vascularity.

4.2. Distribution

Following absorption, drugs distribute according to plasma protein binding, tissue affinity, and blood flow. IV administration provides immediate distribution; oral and other routes introduce delays. Transdermal and topical routes may result in localized tissue concentrations, whereas inhalation can achieve both pulmonary and systemic distribution depending on particle size and formulation.

4.3. Metabolism

Metabolic pathways are route‑dependent. Oral drugs are frequently subjected to hepatic first‑pass metabolism, whereas IV, IM, SC, and inhaled routes may achieve lower first‑pass effects. Transdermal and topical routes can also avoid hepatic metabolism if the drug is not systemically absorbed. For CNS‑directed routes, metabolism may be limited to local enzymatic activity within the CNS.

4.4. Excretion

Renal excretion is the predominant route for many drugs, but hepatic biliary excretion, pulmonary exhalation, and skin excretion can also occur. The route of administration can influence the fraction of drug eliminated via each pathway. For example, inhaled steroids may be exhaled unchanged or metabolized in the lungs, whereas orally administered agents may undergo enterohepatic recirculation.

4.5. Half‑Life and Dosing Considerations

The apparent half‑life is a composite of absorption, distribution, metabolism, and excretion kinetics. IV and inhalation routes often yield shorter apparent half‑lives due to rapid distribution and elimination, necessitating higher or more frequent dosing. Transdermal patches can prolong effective half‑lives by providing a controlled release, reducing dosing frequency. Pediatric and geriatric patients may require dose adjustments based on altered pharmacokinetics.

5. Therapeutic Uses and Clinical Applications

5.1. Oral Administration

Oral delivery is the most common route for chronic diseases such as hypertension, diabetes, dyslipidemia, and infections. It is advantageous for outpatient care and patient convenience, but is limited by poor solubility, instability in gastric acid, and variable absorption.

5.2. Intravenous Administration

IV infusion is essential for acute conditions requiring rapid onset: sepsis, anaphylaxis, thrombolysis, and chemotherapy. It allows precise titration of plasma concentrations and is preferred when oral absorption is unreliable (e.g., severe vomiting, malabsorption).

5.3. Intramuscular and Subcutaneous Administration

IM injections are frequently employed for vaccines, depot antipsychotics, and analgesics. SC injections permit self‑administration of insulin and some biologics. These routes balance rapidity of onset with sustained delivery.

5.4. Transdermal Administration

Transdermal patches are widely used for nicotine replacement therapy, hormone replacement, and analgesics. They are particularly valuable for drugs with fluctuating plasma levels or for patients with swallowing difficulties.

5.5. Topical Administration

Topical agents treat dermatologic conditions such as eczema, psoriasis, and infections. They are also used for localized pain management and for administering local anesthetics.

5.6. Inhalation Administration

Inhaled bronchodilators and corticosteroids are cornerstones of asthma and chronic obstructive pulmonary disease (COPD) management. Inhaled antibiotics and antifungals treat pulmonary infections. Systemic inhalation is utilized for certain chemotherapeutics and for nicotine replacement.

5.7. Transmucosal Administration

Sublingual nitroglycerin and buccal misoprostol are employed for rapid onset in angina and labor induction, respectively. Intranasal fentanyl provides fast analgesia for procedural sedation.

5.8. Intrathecal, Intracerebral, and Intraocular Administration

Intrathecal morphine is used for postoperative pain control. Intracerebral drug delivery is experimental but holds promise for refractory epilepsy and CNS tumors. Intravitreal injections administer anti‑VEGF agents for age‑related macular degeneration.

6. Adverse Effects by Route

6.1. Oral Administration

• Gastrointestinal irritation, nausea, vomiting, and dyspepsia.
• First‑pass hepatic metabolism may produce hepatotoxic metabolites.
• Drug–food interactions can alter absorption.

6.2. Intravenous Administration

• Local infusion reactions (phlebitis, extravasation).
• Systemic adverse effects reflecting peak plasma concentrations.
• Risk of infection or sepsis at catheter sites.

6.3. Intramuscular and Subcutaneous Administration

• Pain, swelling, or hematoma at injection site.
• Local irritation or allergic reactions.
• Variable absorption leading to unpredictable plasma levels.

6.4. Transdermal Administration

• Contact dermatitis or skin irritation.
• Systemic side effects due to prolonged exposure.
• Variable absorption influenced by skin condition and temperature.

6.5. Topical Administration

• Local skin reactions (irritation, allergic dermatitis).
• Systemic absorption can cause systemic toxicity for potent agents.
• Infiltration into non‑target tissues if application technique is inadequate.

6.6. Inhalation Administration

• Bronchospasm, cough, or local irritation.
• Systemic side effects from absorbed drug (e.g., tachycardia with β‑agonists).
• Risk of aspiration or inhalation injury in compromised patients.

6.7. Transmucosal Administration

• Mucosal irritation or ulceration.
• Systemic side effects from rapid absorption.
• Potential for local infection if the mucosa is compromised.

6.8. Intrathecal, Intracerebral, and Intraocular Administration

• Neurological complications such as seizures, meningitis, or neurotoxicity.
• Ocular complications including intraocular pressure elevation or retinal damage.
• Infection risk at the injection site.

7. Drug Interactions by Route

7.1. Oral–Drug Interactions

• Food components (e.g., calcium, iron) can chelate with certain antibiotics, reducing absorption.
• Proton pump inhibitors may alter gastric pH, affecting solubility of weak bases.
• Co‑administration with drugs that induce or inhibit CYP enzymes can modify first‑pass metabolism.

7.2. Intravenous–Drug Interactions

• Concurrent infusion of drugs with overlapping metabolism can lead to accumulation.
• Dilution or compatibility issues between intravenous agents.
• Interaction with catheter lock solutions (e.g., heparin) may affect drug stability.

7.3. Intramuscular and Subcutaneous–Drug Interactions

• Local tissue irritation may be exacerbated by co‑administered agents.
• Absorption of one drug can be altered by the presence of another at the injection site.
• Potential for systemic interactions if both drugs are absorbed into circulation.

7.4. Transdermal–Drug Interactions

• Concurrent use of other transdermal products can alter skin permeability.
• Heat or moisture can increase drug flux, potentiating interactions.
• Skin conditions may affect absorption of co‑administered topical agents.

7.5. Topical–Drug Interactions

• Co‑application of irritants can enhance systemic absorption.
• Competing agents can reduce efficacy of each other via local antagonism.
• Skin barrier disruption can alter drug‑drug interaction profiles.

7.6. Inhalation–Drug Interactions

• Systemic absorption of inhaled agents can lead to interactions with orally or intravenously administered drugs.
• Bronchial deposition of one agent may affect the clearance of another.
• Combination inhalers necessitate careful dose calculations to avoid over‑exposure.

7.7. Transmucosal–Drug Interactions

• Rapid absorption can amplify interactions with systemic medications.
• Local mucosal inhibitors or enhancers can modulate drug levels.
• Co‑administration with drugs that affect mucosal blood flow may alter absorption.

7.8. Intrathecal, Intracerebral, and Intraocular–Drug Interactions

• Local neurotoxic agents can potentiate systemic neurotoxicity.
• Concomitant ocular drugs can influence intraocular pressure or retinal perfusion.
• CSF dynamics may be altered by multiple intrathecal agents, affecting clearance.

8. Special Considerations

8.1. Pregnancy and Lactation

Routes that avoid first‑pass metabolism or systemic exposure are preferred to minimize fetal or neonatal risk. Transdermal and topical routes may reduce systemic levels, but careful assessment of drug transfer into breast milk is required. Intravenous and intramuscular routes provide precise dosing but may increase systemic exposure, necessitating risk‑benefit evaluation.

8.2. Pediatric Considerations

Pediatric patients often have different absorption kinetics, requiring dose adjustments per body surface area or weight. Oral formulations may be preferred when feasible, but taste masking and formulation stability are critical. IM and SC routes are commonly used for vaccines and depot medications. Transdermal patches are less common due to skin thickness variations.

8.3. Geriatric Considerations

Age‑related changes in skin permeability, gastrointestinal motility, and hepatic/renal function affect drug disposition. Reduced hepatic metabolism may increase systemic exposure from oral or transdermal routes. Dependent or frail patients may benefit from simplified regimens such as transdermal or inhalational routes to enhance adherence.

8.4. Renal and Hepatic Impairment

Renal dysfunction can prolong drug half‑life, particularly for drugs eliminated unchanged. Hepatic impairment may affect drugs with significant hepatic metabolism. Routes that bypass first‑pass metabolism, such as IV or transdermal, may be advantageous when hepatic metabolism is a concern. Dosage adjustments should be guided by pharmacokinetic data and therapeutic drug monitoring.

9. Summary / Key Points

• Routes of administration influence drug absorption, distribution, metabolism, and excretion, thereby affecting therapeutic outcomes.
• Oral routes are convenient but subject to first‑pass metabolism and variable absorption; IV routes provide rapid, complete bioavailability.
• Transdermal and topical routes enable localized therapy and sustained release but require careful assessment of skin integrity and systemic absorption.
• Inhalation provides rapid pulmonary delivery and systemic exposure for certain agents; transmucosal routes offer rapid systemic absorption with minimal first‑pass effect.
• Special populations (pregnancy, pediatrics, geriatrics, renal/hepatic impairment) necessitate individualized route selection and dosing strategies.
• Drug interactions can be route‑specific and should be evaluated in the context of absorption kinetics and local tissue effects.
• Adverse effect profiles are closely linked to the route of administration, with local irritation commonly associated with topical, transdermal, and transmucosal therapies.

Clinical decision‑making regarding the route of drug administration should integrate pharmacokinetic principles, therapeutic objectives, patient characteristics, and safety considerations to achieve optimal therapeutic efficacy.

References

1. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
2. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
3. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
4. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
5. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
6. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
7. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
8. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.